Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus

被引：8
|
作者：
Canas, E
Pachon, J
GarciaPesquera, F
Castillo, JR
Viciana, P
Cisneros, JM
JimenezMejias, ME
机构：
[1] HOSP UNIV VIRGEN ROCIO,INFECT DIS UNIT,E-41013 SEVILLE,SPAIN
[2] HOSP UNIV VIRGEN ROCIO,DEPT NUCL MED,E-41013 SEVILLE,SPAIN
[3] HOSP UNIV VIRGEN ROCIO,CLIN PHARMACOL UNIT,E-41013 SEVILLE,SPAIN
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1996年 / 40卷 / 01期
关键词：
D O I：
10.1128/AAC.40.1.230
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Pharmacokinetic parameters of zidovudine (ZDV) were not altered in 16 patients receiving concomitant therapy with ZDV and trimethoprim-sulfamethoxazole by oral administration. ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 mu g . h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively. ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.
引用
收藏
页码：230 / 233
页数：4
相关论文
共 50 条
  • [21] Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection
    Rieder, MJ
    King, SM
    Read, S
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (11) : 1028 - 1031
  • [22] Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients
    Ribera, E
    Fernandez-Sola, A
    Juste, C
    Rovira, A
    Romero, FJ
    Armadans-Gil, L
    Ruiz, I
    Ocaña, I
    Pahissa, A
    CLINICAL INFECTIOUS DISEASES, 1999, 29 (06) : 1461 - 1466
  • [23] EVALUATION OF THE INVIVO EFFECT OF NAPROXEN ON ZIDOVUDINE PHARMACOKINETICS IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    SAHAI, J
    GALLICANO, K
    GARBER, G
    PAKUTS, A
    HAWLEYFOSS, N
    HUANG, L
    MCGILVERAY, I
    CAMERON, DW
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (05) : 464 - 470
  • [24] Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients
    Cato, A
    Qian, J
    Hsu, A
    Levy, B
    Leonard, J
    Granneman, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) : 1788 - 1793
  • [25] Cutaneous adverse reactions and CD4+ cell counts in human immunodeficiency virus-infected patients receiving trimethoprim-sulfamethoxazole
    Caumes, E
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (02) : 530 - 531
  • [26] PHARMACOKINETICS OF THE TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION IN THE ELDERLY
    VAROQUAUX, O
    LAJOIE, D
    GOBERT, C
    CORDONNIER, P
    DUCREUZET, C
    PAYS, M
    ADVENIER, C
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 20 (06) : 575 - 581
  • [27] DESENSITIZATION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN HIV-INFECTED PATIENTS
    ABSAR, N
    DANESHVAR, H
    BEALL, G
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (06) : 1001 - 1005
  • [28] Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin
    Huan-Huan Wu
    Shuang-Yan Fang
    Yan-Xiao Chen
    Lan-Fang Feng
    World Journal of Clinical Cases, 2022, (09) : 2743 - 2750
  • [29] Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas
    Chakwenya, J
    Lakritz, J
    Tyler, J
    Fales, WH
    James-Kracke, M
    Smith, K
    Holle, J
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2002, 25 (05) : 321 - 327
  • [30] Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin
    Wu, Huan-Huan
    Fang, Shuang-Yan
    Chen, Yan-Xiao
    Feng, Lan-Fang
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (09) : 2743 - 2750
12345